Radboud University Nijmegen Medical Centre
|Department of Cognitive Neuroscience|
|Donders Institute for Brain, Cognition and Behaviour|
|Geert Grooteplein-Noord 21|
|6525 EZ Nijmegen, The Netherlands|
|Prof. Jan K. Buitelaar|
|Phone: +31-24-36-10750 or +31-24-36-10655|
|Dr Cees Kan|
|Prof. Rutger Jan van der Gaag|
|Dr Jacqueline de Graaf|
|Dr George Pop|
Description of the organization
The Radboud University Nijmegen Medical Centre (RUNMC) is a leading Dutch institute for medical research. The Department of Psychiatry and the Karakter Child and Adolescent Psychiatry University Centre (both headed by Professor Jan K Buitelaar) are specialized in clinical care and research in neuropsychiatric disorders such as ADHD, Conduct Disorder, Schizophrenia and Autism Spectrum Disorders. This research is embedded in two local research institutes, the Donders Institute for Brain, Cognition and Behaviour, and the Nijmegen Centre for Evidence‐Based Practice. As such, research into the efficacy and safety of medication treatment for psychiatric disorders in children and adolescents and adults is of a high priority.
The Nijmegen outpatient clinics have approximately 400 new child and adolescent ADHD patients and about 200 new adult ADHD patients per year. They have a database of more than 2000 children with ADHD, and 600 adults with ADHD. The clinical and research teams include a total of 30 child and adolescent psychiatrists, 15 adult psychiatrists, 20 senior psychologists, 5 post‐doctoral staff and 20 trainees.
RUNMC (Prof Jan K Buitelaar) has been involved in many international collaborations, including multisite international medication trials (Buitelaar et al 2007; Medori et al 2008; Reyes et al 2006) and NIH sponsored projects on the genetics of ADHD (International Multisite ADHD Genetics – IMAGE, R01MH62873 to Steve Faraone, P.I.) and on gene‐by environment interactions in an Autism Birth Cohort (UO1 NS 047537‐01 to Ian Lipkin, P.I.). Prof Jan Buitelaar has been Principle Investigator of several largescale national research projects, including a screening study for Autism Spectrum Disorder in over 30,000 infants. He is also the Principle Investigator of the Pediatric European Risperidone Study (PERS) which will be funded by FP7. RUNMC also has a great deal of expertise in the management and coordination of FP6 and FP7 Integrated Projects.
Profile of staff members
Jan K Buitelaar (MD, PhD) is a child and adolescent psychiatrist, and Professor of Psychiatry and Child and Adolescent Psychiatry. He is also the Head of the Department of Psychiatry at RUNMC and of the Karakter Child and Adolescent Psychiatry University Centre. He has been involved in numerous medication trials in children and adolescents with ADHD, Conduct Disorder and Autism Spectrum Disorder. Prof. Buitelaar is also Editor‐in‐Chief of the Journal of European Child and Adolescent Psychiatry. Furthermore, Prof. Buitelaar is active in genetic, brain imaging and cognitive studies, and has published over 280 peer‐reviewed papers.
Cees Kan (MD, PhD) is a psychiatrist and Director of the Outpatient Adult ADHD Clinic and is also involved in basic and applied research in adult ADHD.
Rutger Jan van der Gaag (MD, PhD) is a child and adolescent psychiatrist and Professor of Clinical Child and Adolescent Psychiatry. His areas of expertise include medication research in ADHD, Oppositional Defiant Disorder and Conduct Disorder. He is Director of the Outpatient and Inpatient Units for Child Psychiatry.
Jacqueline de Graaf (MD, PhD) is a specialist in internal medicine, and in particular in vascular medicine. She is an expert in vascular reactivity measurements.
George Pop (MD, PhD) is a cardiologist with expertise in 24 hour blood pressure measurements and echocardiography.
Leonie Hennissen (Msc) is a research assistent.
Main tasks in the project
This partner is responsible for WP8 (Cardiovascular Safety). In addition, RUNMC will participate and contribute to WP2, WP3 and WP4.
More than 1500 children, adolescents and adults across all Europe already took part in our study! Thanks to them, we have already gathered lots of information so we can know a lot more about methylphenidate than ever before!
Did you participate in the ADDUCE studies and are you curious about the latest news on the project?
Here you can find some information!
News for children, April 2015
News for adolescents, April 2015
News for parents, April 2015
The third ADDUCE Newsletter is available!
- the prospective open-label methylphenidate pharmacovigilance study: recruitment status and spin-
- the long-term cardiovascular effects of methylphenidate use: study design and participation
and much more in the ADDUCE Newsletter 3, March 2015
WP3: prospective open-label methylphenidate
- WP8: long-term cardiovascular effects of methylphenidate use
and much more in the ADDUCE Newsletter 2, February 2013
17 & 18 APRIL 2016:
ADDUCE Consortium meeting, London - UK
28 - 31 MAY 2015:
5th World Congress on ADHD: from Child to Adult Disorder, Glasgow - Scotland
20 & 21 APRIL 2015:
ADDUCE Consortium meeting, Salina - Italy
21 - 24 MAY 2014:
3rd EUNETHYDIS International Conference on ADHD, Istanbul - Turkey
ADHD and related disorders
19 & 20 MAY 2014:
ADDUCE Consortium meeting, Istanbul - Turkey
3 - 6 OCTOBER 2013:
23rd EUNETHYDIS Network Meeting, Prague Czech Republic
A meeting of the European Network of Hyperkinetic Disorders
6 - 9 JUNE 2013:
4th World Congress on ADHD: from Childhood to Adult Disease, Milan - Italy
4 & 5 JUNE 2013:
ADDUCE Consortium meeting, Milan - Italy
6 & 7 JUNE 2012:
ADDUCE Consortium meeting, Cagliari - Italy
23 MAY 2012:
2nd EUNETHYDIS International Conference on ADHD, Barcelona - Spain